Intensive therapy with ranibizumab, a monoclonal antibody that inhibits vascular endothelial growth factor, fared better than laser therapy alone or laser therapy plus ranibizumab in improving best-corrected visual acuity and foveal thickness in diabetic macular edema patients between 24 and 36 months, a study indicated. The findings in the Archives of Ophthalmology demonstrate that using anti-VEGF agents is safe and effective for treating DME, researchers noted.

Related Summaries